Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Waverley Pharmaceuticals
Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.
Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.